06/06/2024  14:17:28 Var. - Volume Denaro14:29:35 Lettera17:09:58 Capitalizzazione di mercato Dividend Y. Rapporto P/E
38.90EUR - 377
Fatturato: 14,746.08
-Quantità in denaro: - -Quantità in lettera: - 4.17 bill.EUR 4.16% 25.28

Descrizione business

Orion is a globally operating Finnish developer of pharmaceuticals and diagnostic tests – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. It is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's customers are mainly healthcare service providers and professionals such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics and laboratories. Consumers with pets are another important customer group. Orion's main market is Finland, where it is the clear market leader. Orion’s products are marketed in over a hundred countries, and the Group's own human pharmaceuticals sales organisation covers almost all key European markets. In other markets Orion’s products are sold by several collaboration partners. All of Orion's manufacturing plants and most of its R&D operations are in Finland. Orion’s headquarters are in Espoo.
 

Consiglio di amministrazione & Consiglio di sorveglianza

CEO
Liisa Hurme
Consiglio di amministrazione
Jari Karlson, Outi Vaarala, Satu Ahomäki, Virve Laitinen, Juhani Kankaanpää, Olli Huotari
Consiglio di sorveglianza
Mikael Silvennoinen, Ari Lehtoranta, Eija Ronkainen, Hilpi Rautelin, Kari Jussi Aho, Veli-Matti Mattila, Maziar Mike Doustdar, Karen Lykke Sørensen
 

Dati aziendali

Name: Orion Corporation
Indirizzo: Orionintie 1A,FI-02200 Espoo
Telefono: +358-10-4261
Fax: -
E-mail: -
Internet: is.gd/3PivOU
Industria: Healthcare
Settore: Healthcare Providers
Sub settore: Healthcare Providers
Fine dell'anno finanziario: 31/12
Flottante libero: 97.66%
Data dell'IPO: -

Rapporti con gli investitori

Name: Jari Karlson
IR telefono: +358-10-426-2883
IR Fax: -
IR e-mail: -